Anxo Pharmaceutical Co Beneish M-Score Historical Data
The historical data trend for Anxo Pharmaceutical Co's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anxo Pharmaceutical Co Beneish M-Score Chart
|
Anxo Pharmaceutical Co Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Beneish M-Score |
|
Get a 7-Day Free Trial
|
|
|
-2.50 |
-2.44 |
-2.71 |
-2.33 |
-2.45 |
|
Anxo Pharmaceutical Co Semi-Annual Data
|
|
Dec14 |
Dec15 |
Jun16 |
Dec16 |
Jun17 |
Dec17 |
Jun18 |
Dec18 |
Jun19 |
Dec19 |
Jun20 |
Dec20 |
Jun21 |
Dec21 |
Jun22 |
Dec22 |
Jun23 |
| Beneish M-Score |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
- |
-2.33 |
- |
-2.45 |
- |
Competitive Comparison of Anxo Pharmaceutical Co's Beneish M-Score
For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anxo Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Anxo Pharmaceutical Co's Beneish M-Score falls into.
Anxo Pharmaceutical Co Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Anxo Pharmaceutical Co for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 1.0807 | + | 0.528 * 1.0518 | + | 0.404 * 1.2148 | + | 0.892 * 1.0512 | + | 0.115 * 0.9771 |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI |
| - | 0.172 * 0.9789 | + | 4.679 * -0.042541 | - | 0.327 * 1.0174 |
| = | -2.45 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Dec22) TTM: | Last Year (Dec21) TTM: |
Total Receivables was NT$247.7 Mil.
Revenue was NT$866.3 Mil.
Gross Profit was NT$331.5 Mil.
Total Current Assets was NT$771.5 Mil.
Total Assets was NT$1,974.1 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,109.5 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$74.2 Mil.
Selling, General, & Admin. Expense(SGA) was NT$185.7 Mil.
Total Current Liabilities was NT$555.1 Mil.
Long-Term Debt & Capital Lease Obligation was NT$561.7 Mil.
Net Income was NT$-12.6 Mil.
Gross Profit was NT$0.0 Mil.
Cash Flow from Operations was NT$71.4 Mil.
|
Total Receivables was NT$218.0 Mil.
Revenue was NT$824.1 Mil.
Gross Profit was NT$331.7 Mil.
Total Current Assets was NT$704.8 Mil.
Total Assets was NT$1,919.0 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,139.7 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$74.4 Mil.
Selling, General, & Admin. Expense(SGA) was NT$180.4 Mil.
Total Current Liabilities was NT$472.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$594.1 Mil.
|
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (247.671 / 866.274) | / | (218.017 / 824.1) |
| = | 0.285904 | / | 0.264552 |
| | = | 1.0807 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) |
| = | (331.659 / 824.1) | / | (331.458 / 866.274) |
| = | 0.40245 | / | 0.382625 |
| | = | 1.0518 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (771.499 + 1109.513) / 1974.114) | / | (1 - (704.777 + 1139.72) / 1918.994) |
| = | 0.047161 | / | 0.038821 |
| | = | 1.2148 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 |
| = | 866.274 | / | 824.1 |
| | = | 1.0512 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (74.379 / (74.379 + 1139.72)) | / | (74.217 / (74.217 + 1109.513)) |
| = | 0.061263 | / | 0.062698 |
| | = | 0.9771 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (185.659 / 866.274) | / | (180.431 / 824.1) |
| = | 0.214319 | / | 0.218943 |
| | = | 0.9789 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((561.651 + 555.071) / 1974.114) | / | ((594.103 + 472.843) / 1918.994) |
| = | 0.565683 | / | 0.555992 |
| | = | 1.0174 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (-12.558 - 0 | - | 71.423) | / | 1974.114 |
| | = | -0.042541 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Anxo Pharmaceutical Co has a M-score of -2.45 suggests that the company is unlikely to be a manipulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6677 has been successfully added to your